Camardo will also join the company's board of directors. William Lehmann, who most recently served as interim CEO, will continue to serve as president and chief operating officer.
Camardo is currently executive vice president and head of the rare disease and inflammation business units and president of US operations at Horizon Therapeutics (HZNP).
Price: 0.89, Change: +0.05, Percent Change: +6.47
|Virtus Investment Partners' Board Maintains Dividend...|
|--DA Davidson Downgrades Thor Industries to Underper...|
|Baird Adjusts Price Target on TJX to $74 From $78, K...|
|Grab Holdings Q1 Loss Narrows as Revenue Advances; C...|
|BofA Securities Downgrades Physicians Realty Trust t...|